Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).


CSE:RVV - Post by User

Post by cool888on May 16, 2021 6:56pm
202 Views
Post# 33211951

Is Revive in "unofficial" partnership" with Pfizer ? UCSF ??

Is Revive in "unofficial" partnership" with Pfizer ? UCSF ??

Pfizer says 'good reason' to believe in success of anti-viral drug



ATHENS, May 14 (Reuters) - The chief executive of Pfizer Inc said on Friday he had "very good reason" to believe in the success of an oral COVID-19 antiviral therapy by the drugmaker now in an early-stage U.S. trial.

Albert Bourla said last month he was hopeful that a COVID-19 antiviral drug would be available by the end of the year. Pfizer has said the antiviral candidate showed potent activity against SARS-CoV-2, the virus that causes COVID-19, in lab studies.

"Right now we have very good reason to believe that we can be successful," Bourla told an economic forum in Athens via video conference, adding the first results on its efficacy would be available after the summer. (Reporting by Karolina Tagaris, Angeliki Koutantou; editing by James Mackenzie)
https://revivethera.com/2021/05/revive-therapeutics-enters-into-research-agreement-with-ucsf-for-bucillamine-as-potential-treatment-for-severe-covid-19/

https://www.ucsf.edu/news/2017/01/405461/ucsf-pfizer-renew-research-collaboration-citing-progress-drug-discovery-research


 

<< Previous
Bullboard Posts
Next >>